AbbVie Inc. (ABBV) Return on Assets (ROA): 2.67%
Is AbbVie Inc.’s return on assets (ROA) high or low?
AbbVie Inc.'s return on assets (ROA) of 2.67% is 46% below its 5-year average of 4.90%, near the low end of its 5-year range (2.67%–8.53%).
As of Thursday, June 11, 2026. 15.51% below its 12-month average of 3.16%.
ABBV Return on Assets (ROA) Chart
ABBV Average Return on Assets (ROA) Chart
ABBV Current vs Average Return on Assets (ROA) Chart
ABBV Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
2.67%
RETURN ON ASSETS (ROA) AVG TTM
3.16%
RETURN ON ASSETS (ROA) AVG 3Y
4.61%
RETURN ON ASSETS (ROA) AVG 5Y
4.90%
RETURN ON ASSETS (ROA) AVG 10Y
6.73%
RETURN ON ASSETS (ROA) AVG 15Y
9.47%
RETURN ON ASSETS (ROA) AVG 20Y
8.91%
CURRENT VS TTM AVG
-15.51%
CURRENT VS 3Y AVG
-42.15%
CURRENT VS 5Y AVG
-45.53%
CURRENT VS 10Y AVG
-60.33%
CURRENT VS 15Y AVG
-71.81%
CURRENT VS 20Y AVG
-70.04%
ABBV Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $399.86B | 2.67% | 3.16% | 4.61% | 4.90% |
| UnitedHealth Group Incorporated (UNH) | $369.16B | 3.85% | 4.36% | 6.27% | 6.84% |
| Merck & Co., Inc. (MRK) | $298.23B | 6.94% | 13.98% | 10.40% | 10.28% |
| Johnson & Johnson (JNJ) | $577.73B | 10.47% | 10.63% | 12.96% | 11.95% |
| Amgen Inc. (AMGN) | $188.37B | 8.43% | 6.48% | 7.48% | 8.52% |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 6.05% | 6.31% | 6.46% | 7.20% |
| Gilead Sciences, Inc. (GILD) | $156.35B | 16.38% | 7.62% | 7.90% | 6.83% |
| Abbott Laboratories (ABT) | $155.75B | 5.68% | 11.99% | 10.28% | 9.45% |
| Pfizer Inc. (PFE) | $149.61B | 3.61% | 3.75% | 6.08% | 7.08% |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 14.81% | 13.09% | 12.00% | 11.68% |
Asset Efficiency
ROA
2.7%
ROE
13.2%
AbbVie Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for AbbVie Inc. (ABBV)?
- The return on assets (ROA) for ABBV stock is 2.67%.
- Is AbbVie Inc.'s return on assets (ROA) high or low?
- AbbVie Inc.'s return on assets (ROA) of 2.67% is 46% below its 5-year average of 4.90%, near the low end of its 5-year range (2.67%–8.53%).
- What is the TTM average return on assets (ROA) for AbbVie Inc. (ABBV)?
- The TTM average return on assets (ROA) for ABBV stock is 3.16%.
- What is the 3Y average return on assets (ROA) for AbbVie Inc. (ABBV)?
- The 3Y average return on assets (ROA) for ABBV stock is 4.61%.
- What is the 5Y average return on assets (ROA) for AbbVie Inc. (ABBV)?
- The 5Y average return on assets (ROA) for ABBV stock is 4.90%.
- What is the 10Y average return on assets (ROA) for AbbVie Inc. (ABBV)?
- The 10Y average return on assets (ROA) for ABBV stock is 6.73%.
- What is the 15Y average return on assets (ROA) for AbbVie Inc. (ABBV)?
- The 15Y average return on assets (ROA) for ABBV stock is 9.47%.
- What is the 20Y average return on assets (ROA) for AbbVie Inc. (ABBV)?
- The 20Y average return on assets (ROA) for ABBV stock is 8.91%.
AbbVie Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.15% |
| 2024-12-31 | 3.17% |
| 2023-12-31 | 3.61% |
| 2022-12-31 | 8.53% |
| 2021-12-31 | 7.88% |
| 2020-12-31 | 3.07% |
| 2019-12-31 | 8.84% |
| 2018-12-31 | 9.58% |
| 2017-12-31 | 7.50% |
| 2016-12-31 | 9.01% |
| 2015-12-31 | 9.70% |
| 2014-12-31 | 6.45% |
| 2013-12-31 | 14.14% |
| 2012-12-31 | 19.53% |
| 2011-12-31 | 17.59% |
| 2010-12-31 | 19.77% |
| 2009-12-31 | 0.00% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael